共 238 条
[21]
Ruhnke M.(2005)The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland Clin Infect Dis 40 704-708
[22]
Lode H.(2005)Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence Clin Infect Dis 40 709-712
[23]
Fisher N.C.(2006)Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis Med Mycol 44 445-449
[24]
Singhal S.(2008)Late-onset invasive aspergillosis in organ transplant recipients in the current era Clin Transplant 22 1-15
[25]
Miller S.J.(2008)Calcineurin inhibitorsparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity Transplantation 85 15-21
[26]
Hastings J.G.M.(2005)A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression J Antimicrob Chemother 56Suppl1 i49-i54
[27]
Mutimer D.J.(1999)Strategies for managing systemic fungal infection and the place of itraconazole Br J Haematol 105 901-911
[28]
Herbrecht R.(2002)A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group Transplantation 74 688-695
[29]
Denning D.W.(1992)Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients Transplant Proc 24 154-155
[30]
Patterson T.F.(2003)Selective amphotericin B prophylaxis in the reduction of fungal infections after liver transplant J Antimicrob Chemother 52 813-819